Investigational drug · Phase 2
SHJ002
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myopia, Progressive, Corneal Erosion.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
4
Any phase or sponsor naming "SHJ002"
First trial start
2024
Jun 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHJ002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myopia, Progressive
- Corneal Erosion
Largest trials
Live from ClinicalTrials.gov: studies naming "SHJ002" as an intervention, largest first.
- A Study of SHJ002 Sterile Ophthalmic Solution for Myopia ControlPivotal-lookingActive, not recruiting
Sunhawk Vision Biotech, Inc.Industry
NCT06579287 · 140 participants · Start Jan 22, 2025 · Primary completion Dec 2026
Drug: SHJ002; Atropine · For: Myopia, Progressive
Sites: Hillsboro, Ohio; Chang-hua, Taiwan; Kaohsiung City, Taiwan · 9 sites in all
- Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's PatientsPivotal-lookingCompleted
Sunhawk Vision Biotech, Inc.Industry
NCT06381986 · 116 participants · Start Jun 28, 2024 · Primary completion Apr 10, 2025
Drug: SHJ002 · For: Corneal Erosion
Sites: Kaohsiung City, Taiwan; New Taipei City, Taiwan; Taipei, Taiwan · 6 sites in all
Dreamhawk Vision Biotech, Inc.Industry
NCT05486728 · 85 participants · Start Feb 8, 2023 · Primary completion Dec 7, 2023
Drug: SHJ002/Vehicle · For: Dry Eye Disease
Sites: Werribee, Australia; Kaohsiung City, Taiwan; Bangkok, Thailand · 4 sites in all
Sunhawk Vision Biotech, Inc.Industry
NCT04928144 · 12 participants · Start Jul 2, 2021 · Primary completion Sep 17, 2021
Drug: SHJ - Low concentration; SHJ - Mid concentration and 2 more · For: Myopia
Sites: Kaohsiung City, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- Assessing the Efficacy, Safety Profile, and Tolerability of Anti-microRNA-328 Anti-sense (SHJ002) for Dry Eye Disease: A Randomized Phase 2 Trial.
Kasetsuwan N, Jaross N, Reinprayoon U, et al. · Clin Ther 2026
- Quintessence of currently approved and upcoming treatments for dry eye disease.
Patil S, Sawale G, Ghuge S, et al. · Graefes Arch Clin Exp Ophthalmol 2025
- Safety and Tolerability of Anti-microRNA-328 Ophthalmic Solution, SHJ002, in Pediatric Subjects: First-in-Human Clinical Study.
Chen JL, Lai WY, Lin RT, et al. · Clin Ther 2024
Also in development for Myopia, Progressive
- IVMED-85Phase 21 trial
iVeena Delivery Systems, Inc. · Myopia, Progressive
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.